Cita APA

Hernández Prat, A., Rodriguez-Vida, A., Juanpere, N., Arpí Llucià, O., Menéndez, S., Soria-Jiménez, L., . . . Bellmunt Molins, J. (2019). Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models.

Citación estilo Chicago

Hernández Prat, Anna, et al. Novel Oral MTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined With Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. 2019.

Cita MLA

Hernández Prat, Anna, et al. Novel Oral MTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined With Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. 2019.